Hengrui Pharma: Injectable SHR-A1811 and other drugs approved for clinical trials
I'm PortAI, I can summarize articles.
Hengrui Pharma and its subsidiaries recently received approval from the National Medical Products Administration to conduct clinical trials for injectable SHR-A1811, Adalimumab injection, and Famitinib malate capsules. The specific study is an open-label, multicenter Phase 1b/2 clinical trial of injectable SHR-A1811 in combination with anti-tumor drugs for the treatment of solid tumors
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments